Specific immunoadsorbent for myasthenia gravis treatment: Development of synthetic peptide designed to remove antiacetylcholine receptor antibody

Therapeutic Apheresis

Volumn 2, Issue 3, 1998, Pages 246-248

  Miyahara, T ^a   Oka, K ^a   Nakaji, S ^a  

^a KURARAY CO LTD   (Japan)

Author keywords

Acetylcholine receptor; Blocking antibody; Immunoadsorption; Myasthenia gravis; Synthetic peptide

Indexed keywords

BLOCKING ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; SYNTHETIC PEPTIDE;

APHERESIS; ARTICLE; BINDING AFFINITY; DEVICE; IMMUNOADSORBENT; IMMUNOADSORPTION; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031695065     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-9987.1998.tb00113.x     Document Type: Article

References (3)

1. Iida T, Tanaka K, Kitamura M, Two cases of myasthenia gravis with improvement of clinical symptoms by plasmapheresis. Jpn J Kidney Dial 1987;22:735-9.
2. Takamori M, Okumura S, Nagata M. Myasthenogenic significance of synthetic α-subunit peptide 183-200 of Torpedo californica and human acetylcholine receptor. J Neurol Sci 1988; 85:121-9.
3. Ide Y, Okumura S, Takamori M. Treatment of myasthenia gravis with a specific immunoadsorbent bound to acetylcholine receptor peptide a 183-200. Ther Plasmapheresis 1991;9: 147-52.